ArticleHuman vaccines & immunotherapeutics2014
Are cases of mumps in vaccinated patients attributable to mismatches in both vaccine T-cell and B-cell epitopes?: An immunoinformatic analysis.
Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Molecular characterization of Mumps virus genotype C detected from Dibrugarh district of Assam, India.The Indian journal of medical research · 2024Article
- Disentangling the causes of mumps reemergence in the United States.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Exploring the Mumps Virus Glycoproteins: A Review.Viruses · 2022Review
- Streamlined Whole-Genome Sequencing of Mumps Virus for High-Resolution Outbreak Analysis.Journal of clinical microbiology · 2022Article
- Genetic Analysis Reveals Differences in CD8Vaccines · 2021Article
- Structural basis for Glycan-receptor binding by mumps virus hemagglutinin-neuraminidase.Scientific reports · 2020Article
- Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.Frontiers in immunology · 2020Article
- Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?Frontiers in immunology · 2020Review
- Genomic characterization of mumps viruses from a large-scale mumps outbreak in Arkansas, 2016.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2019Article
- Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines.Journal of immunology research · 2019Review
- Monitoring Viral Genetic Variation as a Tool To Improve Molecular Diagnostics for Mumps Virus.Journal of clinical microbiology · 2018Article
- Differences in antigenic sites and other functional regions between genotype A and G mumps virus surface proteins.Scientific reports · 2018Article
- Personalized vaccinology: A review.Vaccine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resurgent mumps outbreaks have raised questions about the current efficacy of mumps vaccines. We have applied immunoinformatics techniques based on principal component analysis to evaluate patterns in predicted B-cell linear epitopes, MHC binding affinity and cathepsin cleavage in the hemagglutinin neuraminidase protein of vaccine strains and wild-type mumps isolates. We have mapped predicted MHC-peptide binding for 37 MHC-I and 28 MHC-II alleles and predicted cleavage by cathepsin B, L and S. By all measures we applied Jeryl-Lynn JL5 major strain is an outlier with immunomic features arising from a small number of amino acid changes that distinguish it from other virus strains. Individuals vaccinated with Jeryl-Lynn who are not exposed to wild-type virus until their protective antibody titer has waned may be unable to recall a protective immune response when exposed to wild-type virus. Dependence on serology to evaluate mumps vaccines may have overemphasized the conservation of one neutralizing antibody epitope, at the expense of monitoring other related changes in the HN protein that could affect recall responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.